在G-CSF中产生EGFR突变肺癌的治疗阻力
Koki Ito1, Kyoichi Kaira1, Hisao Imai1
1Department of Respiratory Medicine, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Saitama, Japan.
Cancer diagnosis & prognosis
|July 4, 2024
概括
具有EGFR突变的颗粒细胞殖民地刺激因子 (G-CSF) 产生的肺癌对向疗法的耐药性. 需要进一步的研究,以了解和克服这些罕见瘤的治疗挑战.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 产生花细胞殖民地刺激因子 (G-CSF) 的瘤是罕见的.
- 具有激活EGFR突变的G-CSF产生的肺癌的临床特征尚不清楚.
研究的目的:
- 描述患者的临床特征和治疗反应的G-CSF产生的肺癌怀有EGFR突变的患者.
主要方法:
- 一个66岁的女性患有G-CSF产生的肺癌和EGFR突变的病例报告.
- 用表皮生长因子受体氨酸激酶抑制剂 (EGFR-TKI) 治疗以及随后的化疗免疫治疗.
主要成果:
- 患者在2-3个月内迅速对EGFR-TKIs (osimertinib,afatinib) 产生抗药性.
- 包括贝瓦西祖马布在内的化疗免疫疗法提供了轻微的生存益处.
结论:
- 具有EGFR突变的G-CSF产生的肺癌对各种治疗方式表现出耐药性.
- 临床医生必须意识到在这些特定的肺癌病例中,对EGFR-TKI治疗的潜在耐药性.
更多相关视频
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
7.9K
08:52Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
Published on: November 22, 2021
4.0K
相关概念视频
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
